Abstract 5740: Identification of genetic signatures in bone metastasis of breast and prostate cancer

• Published in: Cancer research (Chicago, Ill.) Ill.), 2022-06, Vol.82 (12_Supplement), p.5740-5740
• Main Authors: Kähkönen, Tiina E., Halleen, Jussi M., Bernoulli, Jenni
• Format: Article
• Language: English
• ISSN: 1538-7445; 1538-7445
• DOI: 10.1158/1538-7445.AM2022-5740

Bone metastases (BM) cause high mortality and are present in 70-90% of advanced breast and prostate cancer patients. Cancer is a complex genetic disease, and no single gene has been shown to be solely responsible for the initiation, growth or progression of cancer. Therefore, more complete understanding of the multiple genes responsible for disease progression, and more specifically, for the development of BM is needed to support development of diagnostic tools and novel therapeutics for BM. The aim of this study was to identify genetic signatures specific for BM in solid tumors, more specifically in breast cancer (BC) and prostate cancer (PC). Genetic data was obtained from cBioPortal. A dataset of 500 metastatic solid tumors was used based on availability of metastasis-specific biopsy data (Robinson et al. Integrative clinical genomics of metastatic cancer, Nature 2017). Altogether 40 of the patients (8%) had BM, of which 27 (67,5%) with PC and 8 (20%) with BC. All cancer biopsy samples were grouped to ‘BM-only’ (n = 40) and ‘no-BM’ (n = 460) groups, indicating the presence or absence of BM. The same comparisons were made separately for BC and PC. To confirm cancer type specificity of the findings, the BC and PC BM-only data were compared. Only significant findings (p